價格 | 詢價 | ||
包裝 | 20μl | 50μl | 100μl |
最小起訂量 | 1μl |
發(fā)貨地 | 上海 |
更新日期 | 2025-05-27 |
中文名稱:ADAMTS7抗體 | 英文名稱:Rabbit Polyclonal ADAMTS7 Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 6856 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點: ADAMTS7 |
WB | 咨詢技術(shù) | Human,Mouse,Rat |
IF | 咨詢技術(shù) | Human,Mouse,Rat |
IHC | 1/10-1/50 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
Aliases | ADAM-TS7; ADAMTS-7; ADAM-TS 7 |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Synthetic peptide of human ADAMTS7 |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12799(ADAMTS7 Antibody) at dilution 1/20. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P12799(ADAMTS7 Antibody) at dilution 1/20. (Original magnification: ×200)
以下是關(guān)于ADAMTS7抗體的示例參考文獻(xiàn)(內(nèi)容為虛構(gòu),僅供格式參考):
---
1. **文獻(xiàn)名稱**: *ADAMTS7 Inhibition Attenuates Atherosclerotic Plaque Formation*
**作者**: Smith J, et al. (2020)
**摘要**: 研究證明ADAMTS7在血管平滑肌細(xì)胞遷移中起關(guān)鍵作用。通過開發(fā)特異性中和抗體,顯著抑制小鼠動脈粥樣硬化斑塊進(jìn)展,提示其治療潛力。
2. **文獻(xiàn)名稱**: *Monoclonal Antibody Targeting ADAMTS7 Reduces Cartilage Degradation in Osteoarthritis*
**作者**: Lee H, et al. (2018)
**摘要**: 該研究制備了靶向ADAMTS7的單克隆抗體,體外實驗顯示其有效阻斷酶活性,減少軟骨基質(zhì)降解,為骨關(guān)節(jié)炎治療提供新策略。
3. **文獻(xiàn)名稱**: *ADAMTS7 Autoantibodies as Biomarkers in Rheumatoid Arthritis*
**作者**: Garcia R, et al. (2021)
**摘要**: 發(fā)現(xiàn)類風(fēng)濕性關(guān)節(jié)炎患者血清中存在ADAMTS7自身抗體,抗體水平與疾病活動度相關(guān),提示其作為診斷或預(yù)后標(biāo)志物的可能性。
4. **文獻(xiàn)名稱**: *Structural Characterization of ADAMTS7 via Antibody-Based Epitope Mapping*
**作者**: Wang Y, et al. (2019)
**摘要**: 通過抗體表位定位技術(shù)解析ADAMTS7的功能結(jié)構(gòu)域,揭示其底物結(jié)合區(qū)域,為開發(fā)高特異性治療抗體奠定基礎(chǔ)。
---
(注:以上文獻(xiàn)及作者為虛構(gòu)示例,實際引用需查詢真實數(shù)據(jù)庫如PubMed、Web of Science。)
The ADAMTS7 antibody is a research tool designed to detect and study ADAMTS7. a member of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin Motifs) family of extracellular proteases. ADAMTS7 is implicated in extracellular matrix (ECM) remodeling, inflammation, and pathologies such as osteoarthritis, atherosclerosis, and cancer. Its enzymatic activity degrades cartilage oligomeric matrix protein (COMP) and other ECM components, influencing tissue structure and cellular signaling. Dysregulation of ADAMTS7 is linked to vascular calcification, joint degeneration, and tumor progression, making it a potential therapeutic target.
Antibodies against ADAMTS7 are commonly used in techniques like immunohistochemistry, Western blotting, and ELISA to assess protein expression, localization, and activity in biological samples. These antibodies often target specific domains, such as the catalytic metalloproteinase domain or thrombospondin type-1 motifs, enabling functional studies on protease activity or protein-protein interactions. Monoclonal and polyclonal variants are commercially available, with validation data confirming specificity in human, mouse, or rat models.
Recent studies highlight ADAMTS7's role in cardiovascular diseases, particularly atherosclerosis, where its overexpression correlates with plaque instability. In arthritis, it contributes to cartilage breakdown, spurring interest in inhibitory antibodies for disease modification. Researchers also explore its utility as a biomarker for disease progression. However, challenges remain in understanding its full mechanistic spectrum and optimizing antibody-based therapies. Ongoing work aims to clarify its dual roles in tissue homeostasis and pathology, driving demand for reliable ADAMTS7-targeting reagents.
成立日期 | 2024-07-02 (2年) | 注冊資本 | 20萬人民幣 |
員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 抗體,植物生物技術(shù),細(xì)胞培養(yǎng),蛋白組學(xué) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥960.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-08-11 | |
詢價 |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1800 |
VIP1年
|
費雪(杭州)醫(yī)學(xué)研究有限公司
|
2025-07-28 |